NCT06678048招募中2 期
A Single-Arm, Two Stage, Phase II Study of Arsenous Acid Combined With Palliative Chemotherapy for Refractory Triple-Negative Breast Cancer
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年10月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment.
详细描述
The study is a Single-arm, two-stage, Phase II clinical trial. The main purposes of this study are to assess the efficacy and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment. Palliative chemotherapy regimen includes Eribulin, Gemcitabine, Utidelone and Vinorelbine, by the treatment of physician's choice (TPC). This study is designed based on Bayesian probability and divided into two stages. All patients will undergo tumor efficacy assessment every two cycles of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Understands and voluntarily signs the informed consent form.
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0 or
- •Life expectancy greater than 3 months
- •Histologically or cytologically confirmed metastatic invasive breast cancer, with negative for hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). HR negative is defined as Immunohistochemistry (IHC) for estrogen receptor (ER) and/or progesterone receptor (PR) showing < 1% of tumor cells. HER2 negative is defined as IHC 0 or 1+, or IHC 2+ with a negative in-situ hybridization.
- •Refractory to at least two prior standard therapeutic regimens for metastatic disease. For TNBC patients with a programmed death-ligand 1 (PD-L1/22C3) positive result (combined positive score, CPS ) ≥10, eligibility requires prior treatment with chemotherapy combined with PD-
- •Additionally, TNBC patients with a known germline breast cancer susceptibility gene (BRCA) mutation, who are assessed to be unsuitable for or unable to receive poly (ADP-ribose) polymerase (PARP) inhibitor therapy by the physician, also qualify for the study. Recurrence within 12 months following TNBC adjuvant therapy is considered as first-line therapy.
- •Eligible for one of the chemotherapy options listed as palliative chemotherapy (Eribulin, Gemcitabine, Utidelone, Vinorelbine) as per investigator assessment.
- •Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). At least one lesion must not have received prior radiotherapy and should qualify as a baseline lesion according to RECIST 1.1 criteria, with a measurable longest diameter of ≥10 mm on CT or MRI (for lymph nodes, the short axis must be ≥15 mm). Patients with only bone metastases are eligible for enrollment, as are patients with stable brain metastases.
- •Patients must have adequate bone marrow reserves and normal organ function, as defined by the following criteria: Hemoglobin ≥ 9.0 g/dL. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L. Platelet count ≥ 100 × 10^9/L. Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN). Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN, except in cases of Hepatitis B Virus (HBV). For patients with liver metastases, ALT and AST ≤ 5 × ULN.
- •Premenopausal women can use medically acceptable methods of contraception during the study.
- •Demonstrates good compliance.
排除标准
- •Uncontrolled hypertension, persistent or active infections.
- •Persistent toxicities from prior antitumor treatments (excluding alopecia) that have not improved to Grade ≤ 2 or baseline levels, such as hearing loss, neuropathy, or immune-related toxicities (hypothyroidism/hyperthyroidism, hyperglycemia, adrenal insufficiency, etc.).
- •Tumor-related spinal cord compression or active brain metastases.
- •Significant third-space fluid retention (e.g., ascites or pleural effusion) deemed by the investigator to be unsuitable for study participation.
- •Uncontrolled infections requiring intravenous antibiotics, antivirals, or antifungals.
- •Participants known to be human immunodeficiency (HIV) positive, hepatitis B positive, or hepatitis C positive.
- •Uncontrolled or significant cardiac disease, including myocardial infarction or unstable angina within the last six months, congestive heart failure, severe arrhythmias, or uncontrolled hypertension (resting systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg).
- •Suspected interstitial lung disease (ILD) or non-infectious pneumonia that cannot be ruled out and requires corticosteroid treatment.
- •Active autoimmune diseases or inflammatory conditions (including inflammatory bowel disease, systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, rheumatoid arthritis, uveitis, autoimmune non-infectious pneumonia, and autoimmune myocarditis).
- •Concurrent treatment with any other antitumor therapies.
- •Subjects deemed unlikely to comply with the study procedures and requirements by the investigator.
研究组 & 干预措施
Arsenous Acid plus Chemotherapy
Experimental
Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
干预措施: Arsenous Acid plus Chemotherapy (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: 10 months
Progression-Free Survival (PFS) was defined as the time from enrollment until objective tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death, whichever came first.
次要结局
未报告次要终点
研究者
Zhong-yu Yuan
Sun Yat-sen University Cancer Center
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal CancerColorectal CancerNCT00940303Hoffmann-La Roche97
已完成
2 期
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineNon Small Cell Lung CancerNCT00753714Genzyme, a Sanofi Company124
已完成
2 期
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabPreviously Treated Metastatic Adenocarcinoma of the PancreasNCT02243371Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins93
终止
2 期
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyChronic Lymphocytic LeukemiaNCT02742090TG Therapeutics, Inc.51
撤回
2 期
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Resistant Prostate CancerNCT01663415Astellas Pharma Global Development, Inc.